wood mouse eating peanuts
Source: Pixabay/Alexas_Fotos

Immunotherapy

Promising vaccine suppresses peanut allergies in mice

Researchers aim to develop a new immunotherapy that could alter the immune reactions to food. The result: extended relief from peanut allergies.

A vaccine may successfully turn off peanut allergy in mice, a new study shows. Just three monthly doses of a nasal vaccine protected the mice from allergic reactions upon exposure to peanut, according to research from the Mary H. Weiser Food Allergy Center at the University of Michigan. The study, funded by grants from Food Allergy Research and Education (FARE) and the Department of Defense, was published in the Journal of Allergy and Clinical Immunology.

Researchers from Michigan Medicine - University of Michigan (U-M) have spent nearly two decades developing a vaccine agent and have recently translated this work to the development of a vaccine to treat food allergies. In the new study, immunizing peanut allergic mice can redirect how immune cells responded to peanuts in allergic mice. The new approach activates a different type of immune response that prevents allergic symptoms.

Our goal is to use immunotherapy to change the immune system’s response by developing a therapeutic vaccine for food allergies

Jessica O’Konek

“We’re changing the way the immune cells respond upon exposure to allergens,” says lead author Jessica O’Konek, Ph.D. a research investigator at the food allergy center. “Importantly, we can do this after allergy is established, which provides for potential therapy of allergies in humans. By re-directing the immune responses, our vaccine not only suppresses the response but prevents the activation of cells that would initiate allergic reactions.”

The mouse models studied responded to peanut allergies similarly as affected humans, with symptoms that included itchy skin and trouble breathing.  The study assessed protection from allergic reactions two weeks after the final dose of vaccine was administered. Studies to determine duration of protection are ongoing, but researchers are encouraged that this approach will lead to long-lasting suppression of allergies.  

The findings are another step toward a potential clinical trial down the road to test the method in humans. “Right now, the only FDA approved way to address food allergy is to avoid the food or suppress allergic reactions after they have already started,” O’Konek says. “Our goal is to use immunotherapy to change the immune system’s response by developing a therapeutic vaccine for food allergies.”

Next steps include further studies in mice to better understand the mechanisms responsible for the suppression of food allergies and learn whether protection from peanut allergies can be extended for an even longer period of time. “Food allergy has exploded in prevalence and incidence but we still know so little about it because there hasn’t been that much research in the field,” says senior author James Baker, Jr., M.D., director of the U-M Mary H. Weiser Food Allergy Center and who is also the CEO of FARE. “This research is also teaching us more about how food allergies develop and the science behind what needs to change in the immune system to treat them.”


Source: Michigan Medicine - University of Michigan

11.04.2018

Read all latest stories

Related articles

T cell response

Scientists find out what makes people survive Ebola

Scientists conducting the first comprehensive study of key immune system cells—collected from West African Ebola survivors— have made a surprising discovery that provides important clues to…

Immunotherapy response prediction

Pulling the "molecular brake" on tumor cells

An unexpected discovery that could bring new hope to cancer patients worldwide: Researchers from the University of California San Diego have identified a mechanism that could predict response to…

"WAKE-UP"

Study provides new treatment option for stroke patients

In an international study, scientists of the University Medical Center Hamburg-Eppendorf (UKE) have discovered a new therapeutic option for a large group of stroke patients. The main results of the…

Related products

Immunochemistry

Beckman Coulter - Anti-Mullerian Hormone (AMH)

Beckman Coulter, Inc.

Immunochemistry

Beckman Coulter - phi (Prostate Health Index)

Beckman Coulter, Inc.

Clinical chemistry

DiaSys Diagnostic Systems - BioMajesty JCA-BM6010/C

DiaSys Diagnostic Systems GmbH

Clinical chemistry

DiaSys Diagnostic Systems - respons910

DiaSys Diagnostic Systems GmbH